Neratinib + endocrine therapy

DRUG2 trials

Sponsors

SOLTI Breast Cancer Research Group, University of California, San Diego

Conditions

Breast CancerER+, HER2-, Metastatic Breast CancerMetastatic Invasive Breast CancerResistant Breast Cancer

Phase 2

Targeting EGFR/ERBB2 With Neratinib in Hormone Receptor (HR)-Positive/HER2-negative HER2-enriched Advanced/Metastatic Breast Cancer

TerminatedNCT04460430

SOLTI Breast Cancer Research GroupBreast Cancer

Start: 2020-07-23End: 2021-11-29Updated: 2022-10-25

Neu Direction: Testing the Efficacy of Adding HER Inhibition to Standard of Care in Metastatic MLH1-low Endocrine-resistant ER+/HER2- Breast Cancer

Not yet recruitingNCT07729046

University of California, San DiegoER+, HER2-, Metastatic Breast Cancer, Metastatic Invasive Breast Cancer, Resistant Breast Cancer

Start: 2027-07-01End: 2035-06-01Target: 150Updated: 2026-07-27

Related Papers

Abstract PO3-05-07: SOLTI-1718 NEREA Trial: Neratinib in hormone receptor (HR)-positive/HER2-negative HER2-enriched (HER2-E) advanced breast cancer (BC)

Cancer Research2024-05-021 citations

Abstract PO3-14-07: Characterizing Immune Infiltration in Metastatic Hormone Receptor-Positive/HER2-Negative Breast Cancer: A Comprehensive Translational Analysis from four SOLTI Clinical Trials

Cancer Research2024-05-02

Abstract OT2-27-01: Solti-1718 NEREA Trial: Neratinib in hormone receptor (HR)-positive/HER2-negative HER2-enriched (HER2-E) advanced breast cancer (BC)

Cancer Research2022-02-151 citations